@article {2014, title = {Effect of Thiamine on Serum Glutamate in Ischemic Stroke Animal Model}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {April 2023}, pages = {390-392}, type = {Research Article}, chapter = {390}, abstract = {

Background: Thiamin or vitamin b1 is a therapy that has been widely used in neurology cases such as alcohol-induced encephalopathy and neuropathy. Thiamin has the ability to penetrate the blood brain barrier so that it is expected to be used as an additional therapy in stroke cases. Stroke is currently an emergency neurology case that causes high mortality and disability. Among the causes is because damage to large areas of the brain will cause the release of neurotransmitters such as glutamate which has excitotoxicity effects to the brain when excessive. Method: This study used animal models of carotid artery occlusion stroke. Divided into 4 groups: control, thiamin dose of 100mg/kg, Thiamin 200mg/kg, and 400mg/kg. Serum glutamate was collected on day 7 post-action. Then evaluated by ELISA method. Results: There was a significant difference in the form of a decrease in the average serum glutamate level between the control and the sample that received a dose of thiamine 200mg/kg and 400mg/kg. Conclusion: High-dose thiamine may be considered as an additional therapy in cases of carotid artery occlusion model stroke.

}, keywords = {Animal model, Glutamate, Ischemic, Stroke., Thiamine}, doi = {10.5530/pj.2023.15.60}, author = {Mohammad Saiful Ardhi and Muhammad Hamdan and Achmad Chusnu Romdhoni} } @article {2161, title = {The Influence of Vitamin D3 Administration on the Levels of CGRP, Glutamate, and NLRP3 during the Ictal Phase in Chronic Migraine Patients}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {December 2023}, pages = {1052-1058}, type = {Original Article}, chapter = {1052}, abstract = {

Background: Migraine is a primary headache disorder that ranks as the third leading cause of disability. Various prophylactic therapies have been developed for migraine treatment, including vitamin D3 supplementation. The mechanism of action of vitamin D3 supplementation in the pathophysiology of migraine has not been extensively studied. Objective: This study assesses the impact of vitamin D3 administration on the levels of the biomarkers CGRP, Glutamate, and NLRP3 and its effect on reducing the frequency and intensity of migraine attacks in chronic migraine patients. Methods: This experimental study (single-blind clinical trial) observes two groups: a group given vitamin D3 at 2000 IU for 12 weeks and a placebo group. This study involved 61 chronic migraine subjects. At the end of the study, after excluded 31 subjects, there were 12 subjects in each of the two groups. Results: A significant relationship was found between vitamin D3 administration and the reduction in the frequency and duration of migraine attacks in both the vitamin D3 group (p\<0.001) and the placebo group (p=0.078). No significant relationship was found between vitamin D3 administration and changes in CGRP levels (p=0.633), but there were significant changes in glutamate (p\<0.001) and NLRP3 (p=0.016) levels following vitamin D3 administration. Conclusion: Vitamin D3 supplementation has an impact on reducing the frequency and duration of migraine attacks in chronic migraine patients, and there is a significant association with changes in glutamate and NLRP3 levels, but not with changes in CGRP levels.

}, keywords = {CGRP, Chronic Migraine, Glutamate, NLRP3, Vitamin D3}, doi = {10.5530/pj.2023.15.193}, author = {Restu Susanti and Yuliarni Syafrita and Afriwardi and Rauza Sukma Rita and Eryati Darwin and Nur Indrawaty Lipoeto and Hirowati Ali and Fika Tri Anggraini} } @article {504, title = {Ameliorative Role of Vitamin D on Prenatal and Postnatal Exposure of Monosodium Glutamate Induced Steatohepatitis in Rat Pups}, journal = {Pharmacognosy Journal}, volume = {10}, year = {2018}, month = {January 2018}, pages = {371-375}, type = {Original Article}, chapter = {371}, abstract = {

Background: Monosodium glutamate (MSG) is a widely used flavor enhancer has been linked to obesity and metabolic syndrome, including progressive liver disease. Nonalcoholic Fatty Liver Disease (NAFLD) is the most common hepatic disorder with an etiology related to changes in diet and lifestyle. Prenatal and postnatal exposure to MSG been shown to affect developing tissues in growing animals. Increased Risk of Non-alcoholic Steatohepatitis has been associated with Vitamin D deficiency. The present study was aimed to investigate the ameliorative effect of vitamin D on MSG induced animal models of steatohepatitis in neonatal rats. Materials and Methods: Eighteen nulliparous female wistar rats were randomly divided into three groups (n=6/group). Group-I received a daily oral dose of 5g/kg body weight of MSG. Group-II received the same dose of MSG along with calcitriol (0.2\μg/kg BW). Group-III was treated with saline served as the control. The rats could mate, and treatment was given for the entire period of gestation and thirty days thereafter, during lactation. The histological changes in the liver was observed. Results: Pan-lobular microvesicular steatosis, lobular inflammation and ballooning of hepatocytes was observed in the MSG-treated group. These histotoxic changes were ameliorated in the vitamin D treated group. Conclusion: Vitamin D might be beneficial in the protection of the pre-and postnatal exposed MSG induced steatohepatitis. Further, induction of steatohepatitis in a shorter period could also make it an ideal study model of non-alcoholic steatohepatitis.

}, keywords = {Gestation, Glutamate, MSG, Steatohepatisis, Vitamin D}, doi = {10.5530/pj.2018.2.62}, url = {http://fulltxt.org/article/493}, author = {Nandan Padmanabha and Nirupama Muralimunglimane and Nayanatara Arun Kumar and Bhagyalakshmi Kodavanji and Jyoti Ramnath Kini and Roopesh Poojary} }